| ［1］ |
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions［J］. Clin Pharmacol Ther, 1981,30（2）:239⁃245. doi: 10.1038/clpt.1981.154.
|
| ［2］ |
Noël M, Gagné C, Bergeron J, et al. Positive pleiotropic effects of HMG⁃CoA reductase inhibitor on vitiligo［J］. Lipids Health Dis, 2004,3:7. doi: 10.1186/1476⁃511X⁃3⁃7.
|
| ［3］ |
Agarwal P, Rashighi M, Essien KI, et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo［J］. J Invest Dermatol, 2015,135（4）:1080⁃1088. doi: 10.1038/jid.2014. 529.
|
| ［4］ |
Vanderweil SG, Amano S, Ko WC, et al. A double⁃blind, placebo⁃controlled, phase⁃II clinical trial to evaluate oral simvastatin as a treatment for vitiligo［J］. J Am Acad Dermatol, 2017,76（1）:150⁃151.e3. doi: 10.1016/j.jaad.2016.06.015.
|
| ［5］ |
Iraji F, Banihashemi SH, Faghihi G, et al. A comparison of betamethasone valerate 0.1% cream twice daily plus oral simvastatin versus betamethasone valerate 0.1% cream alone in the treatment of vitiligo patients［J］. Adv Biomed Res, 2017,6:34. doi: 10.4103/2277⁃9175.203159.
|
| ［6］ |
Nguyen S, Chuah SY, Fontas E, et al. Atorvastatin in combination with narrowband UV⁃B in adult patients with active vitiligo: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（6）:725⁃726. doi: 10.1001/jamadermatol.2017.6401.
|
| ［7］ |
刘薇, 刘佳玮, 钱玥彤, 等. 白癜风药物治疗进展［J］. 中华皮肤科杂志, 2018,51（11）:849⁃852. doi: 10.3760/cma.j.issn.0412⁃4030.2018.11.027.
|
| ［8］ |
彭程, 罗朝利. 氟伐他汀致肌触痛、色素沉着1例［J］. 中国新药杂志, 2002,11（3）:239⁃239. doi: 10.3321/j.issn:1003⁃3734. 2002.03.022.
|
